Online Trial Tracker - Larvol Sigma

Welcome, Profile Billing Logout

1 Trials

Active Trials Industry lead sponsorIndustry collaborator

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Demyelinating Autoimmune Diseases, CNS

NCT02807285: Expanded Access Program for Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

No Longer Available

N/A

Ocrelizumab, RO4964913

Genentech, Inc.

Multiple Sclerosis

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites